Funder: Breakthrough T1D
Due Dates: January 7, 2026 (Letter of Intent) | February 24, 2026 (Full proposal)
Funding Amounts: Up to $900,000 total for up to 3 years; level varies by project scope; 10% indirect cost cap for nonprofits.
Summary: Supports development of immune tolerance strategies for islet cell replacement in type 1 diabetes, aiming to enable graft-specific protection without broad immunosuppression.
Key Information: LOI is required and must be approved before full proposal submission.